MedPageToday -- Patients with HER2-positive breast cancer had significantly better disease-free survival four years after adjuvant treatment with trastuzumab (Herceptin), according to long-term follow-up from a large randomized trial. The latest follow-up data, from more than 3,400 study patients, showed a 24% reduction in the hazard ratio among those who received a year of trastuzumab after primary therapy versus women who were merely observed, reported Luca Gianni, MD, of San Raffaele Institute in Milan, Italy, and colleagues.
